ARN-509

Phase 2Small molecule

AAragon Pharmaceuticals, Inc.

ARN-509 is one of 30 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

ARN-509

AAragon Pharmaceuticals, Inc.

Phase 2

4 10

Triptorelin Pamoate

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

Completed·—·Phase 2·NCT03098836·93 enrolled

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Completed·AAragon Pharmaceuticals, Inc.·Phase 1/2·NCT01171898·127 enrolled

AASUR in High Risk Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02772588·64 enrolled

Show 1 more trial

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Completed·AAragon Pharmaceuticals, Inc.·Phase 2·NCT01790126·90 enrolled

Prostatectomy1 trial

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03080116·90 enrolled

Abiraterone Acetate1 trial

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

Completed·AAragon Pharmaceuticals, Inc.·Phase 1·NCT01792687·6 enrolled

Unspecified1 trial

14C-ARN-509 Microtracer Label AME and Absolute BA Study

Completed·AAragon Pharmaceuticals, Inc.·Phase 1·NCT01822041·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for ARN-509. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARN-509 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARN-509. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aragon Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAragon Pharmaceuticals, Inc.

ARN-509

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer4 trials

Prostatectomy1 trial

Abiraterone Acetate1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News